Treatment of recurrent oral aphthous ulcers with etanercept [3]

Clinical and Experimental Rheumatology

Volumn 20, Issue 5, 2002, Pages 733-734

  Scheinberg, M A ^a  

^a Center for Clinical Immunology   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; APHTHOUS ULCER; BEHCET DISEASE; CONTROLLED STUDY; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG USE; HUMAN; IMMUNOMODULATION; LETTER; MUSCLE WEAKNESS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT DISEASE; TERATOGENICITY;

BEHCET SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; STOMATITIS, APHTHOUS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0036709099     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. KOCH HP: Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985; 22: 165-242.
2. TSENG S, PAK G, WASHENIK K: Rediscovering thalidomide. A review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1966; 35: 969-79.
3. SAMPAIO EP, SARNO EM, GALILLY R, et al.: Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
4. MOREIRA AL, SAMPAIO EP, ZMUIDZIMAS A, et al: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
5. MORELAND LW: Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999; 26: 7-15.
6. MAINI RN, TAYLOR PC: Anti cytokine therapy in rheumatoid arthritis. Ann Rev Med 2000; 51: 207-29.
7. ROBERTSON LP, MICKLING P: Treatment of recalcitrant, orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology 2001; 10: 473-4.